Insilico Medicine begins clinical trial for AI-designed cancer drug ISM3412 Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), today announces that the first patient has been dosed in a global multicenter clinical trial (NCT0641446 to evaluate ISM3412, a potentially best-in-class, AI-empowered MAT2A inhibitor with novel structure, in patients with locally advanced and metastatic solid tumors.
https://www.news-medical.net/n....ews/20250627/Insilic